Home

overview

Join us for a 60-minute live symposium, featuring expert faculty who will discuss the challenges encountered by care decision-makers in optimizing patient outcomes when managing schizophrenia symptoms. How do treatments with innovative mechanisms of action impact patients’ quality of life, treatment-related adverse events, comorbidities, and adherence? These topics will be highlighted during the experts’ dynamic conversation, followed by a Q&A session.

faculty

MODERATOR

Roger S. McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology at the University of Toronto; Head of the Mood Disorders Ps

FACULTY

Catherine Cooke, PharmD, BCPS, PAHM

Research Associate Professor of Practice, Sciences, and Health Outcomes Research; School of Pharmacy

Research Associate Professor of Practice, Sciences, and Health Outcomes Research

School of Pharmacy, The University of Maryland,

Baltimore, MD

FACULTY

Megan Ehret, PharmD, MS, BCPP

Professor of Practice, Sciences, and Health Outcomes Research Co-director, Mental Health Program; Sc

AGENDA

11:30 am

Lunch and Registration

12:00 pm

Presentation: “Strategic Approaches for Managed Care Providers in Managing Schizophrenia in the New Era of Treatments”

12:50 pm

Questions and Answer Session

GOAL STATEMENT

The goal of this activity is for managed care decision-makers to be better prepared to recognize the multifaceted challenges for schizophrenia management, including its impact on quality of life, treatment-related adverse events, and comorbidities, and ultimately be key players in improving patient adherence and outcomes via various drug utilization strategies, including novel agents.

TARGET AUDIENCE

This educational activity is primarily intended for an audience of managed care pharmacy stakeholders (pharmacists, payers, pharmacy benefit managers and others) and extended to other healthcare providers managing schizophrenia including those in psychiatry.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: [break] [break] Have increased knowledge regarding the [LIST] [ITEM]Economic burden of schizophrenia based on currently available treatment paradigms and their limitations  [ITEM]Impact on untreated/poorly treated schizophrenia patients, including the burden of residual symptoms   [ITEM]Evidence for new/emerging schizophrenia treatments [/LIST] [break] Have greater competence related to [LIST] [ITEM]Evaluating the roles of managed care providers in improving schizophrenia outcomes [/LIST] [break] Demonstrate greater confidence in their ability to [LIST] [ITEM]Recognize where new/emerging treatments may fit into schizophrenia care [/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Pharmacists[/bold][break] Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-301-L01-P).

CPE